Stocktoria
BioCardia, Inc. BCDA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-11-13
BioCardia, Inc. statistics & valuation
Market cap$17.9M
P / B20.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -13794.8% | -2441.1% | -880.3% | -1244.3% |
| Net margin | — | -13700.0% | -2425.8% | -880.7% | -1243.6% |
| FCF margin | — | -13606.9% | -2093.5% | -786.3% | -1032.7% |
| Return on assets | -241.1% | -213.4% | -387.4% | -121.6% | -80.3% |
| Return on equity | -919.3% | -949.3% | 721.8% | -243.4% | -121.7% |
| Current ratio | 1.12 | 1.13 | 0.40 | 2.19 | 3.63 |
| Revenue growth | -100.0% | -87.8% | -64.7% | 33.2% | 600.0% |
Source: SEC EDGAR filings · CIK 0000925741 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.